Reviewer's report

Title: Blood Consumption in Total Arterial Coronary Artery Bypass Grafting

Version: 0 Date: 14 Oct 2019

Reviewer: Atif Akcevin

Reviewer's report:

The sentence concerning with the lines 69-73 ,may be revised as " While the first randomized trial on CAGB survival at 10 years between BIMA and SIMA, the Arterial Revascularization Trial (ART), still awaits its outcome data, the analysis of clinical and safety outcomes after 5 years shows no significant differences in the rates of death, stroke or myocardial infarction between the bilateral- and single-arterial graft groups ."

The sentence concerning with the lines 96-97, may be revised as " We excluded patients with single-vessel coronary artery disease (N=40) since these patients were commonly only grafted with a single conduit. "

The sentence concerning with the lines 101-104, may be revised as " Within our study population, patients were attributed to two groups. The group undergoing total arterial CAGB includes patients who were revascularized using exclusively BIMA conduits (N=419) and the mixed CAGB group includes patients who received a composition of SIMA and SV conduits (N=176)."

The sentence concerning with the lines 134-135, may be revised as " No sealant at all was used for hemostasis and clipping was preferred for bleeding control whenever possible. "

Concerning with the lines 172-173, the term of "anticoagulation" may be replaced with the term of "anticoagulation and antiaggregation regimen".

Concerning with the line 212, the term of "anticoagulant" may be replaced with the term of"anticoagulant and antiaggregant".

Concerning with line 260, the term of "anticoagulation scheme " may be replaced with the term of "anticoagulation and antiaggregation scheme".

In table 1, the variable of "anticoagulation" may be as "anticoagulation and antiaggregation"

Level of interest
Please indicate how interesting you found the manuscript:

An article whose findings are important to those with closely related research interests

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

'I declare that I have no competing interests'

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal